Burrage Capital Management’s Harmony Biosciences HRMY Stock Holding History

Burrage Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-150,000	Closed	-$4.23M	–	9
2021 Q2	$4.23M	Hold	150,000	–	–	4.25%	10
2021 Q1	$4.96M	Buy	+150,000	New	+$5.26M	4.02%	10

Other funds holding HRMY

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Burrage Capital Management's HRMY Position: Q3 2021 in Review

Burrage Capital Management sold out of Harmony Biosciences (HRMY) in Q3 2021, closing a stake of 150,000 shares — an estimated $4.23M sold.

Burrage Capital Management first reported a position in HRMY in Q1 2021 and held it in 2 quarters. The position peaked at $4.96M in Q1 2021. 102 funds tracked by Wall St. Rank hold HRMY as of Q3 2021.

Burrage Capital Management reported no remaining Harmony Biosciences position as of Q3 2021 after selling out during the quarter.
Burrage Capital Management sold 150,000 Harmony Biosciences shares in Q3 2021, an estimated $4.23M.
Burrage Capital Management first reported a position in Harmony Biosciences in Q1 2021 and held it in 2 quarters.
Burrage Capital Management's Harmony Biosciences position peaked at $4.96M in Q1 2021.
102 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.